v. 4, n. 82, 2024

International Journal of Health Science

IMPACT OF MECHANICAL THROMBECTOMY ON THE PROGNOSIS OF PATIENTS WITH ISCHEMIC STROKE: A COMPREHENSIVE REVIEW OF THE CURRENT LITERATURE

Leonardo Lucas Pereira Filho
http://lattes.cnpq.br/4022430994941735

Isabela Massarotti
https://lattes.cnpq.br/0011411041304167

Vanessa Martins Pereira Cruz
http://lattes.cnpq.br/7022061170941907

Melyssa Aryane de oliveira
http://lattes.cnpq.br/9531560727825211

Caio Pedral Sampaio Sgarbi
http://lattes.cnpq.br/0052341940121008

River Guilherme Ribeiro
http://lattes.cnpq.br/7146307762094866

Ana Eliza de Pádua
https://lattes.cnpq.br/6927575414364517

Nara Fernanda Alencar da Costa Pinheiro
http://lattes.cnpq.br/6493513370859829

Maykon Pablo Aguiar Fenelon
http://lattes.cnpq.br/5219996141663444

Wilson Jolando Ojeda Júnior
https://lattes.cnpq.br/3730550452281724

Leticia Saura

Laís Chaves Oliveira

Abstract: INTRODUCTION The introduction outlines the significant burden of ischemic stroke globally, emphasizing the limitations of traditional treatments such as intravenous thrombolysis. It highlights the evolution and clinical adoption of mechanical thrombectomy as a revolutionary endovascular treatment for large vessel occlusions. The discussion includes the importance of early intervention, patient selection based on advanced imaging techniques, and the impact of thrombectomy on the organization of acute stroke care systems. The introduction also touches on ethical considerations and disparities in access to thrombectomy services. **OBJETIVE** To provide a comprehensive review of the impact of mechanical thrombectomy on the prognosis of patients with ischemic stroke, focusing on functional outcomes, mortality rates, and long-term recovery. **METHODS** This is a narrative review which included studies in the MEDLINE – PubMed (National Library of Medicine, National Institutes of Health), COCHRANE, EMBASE and Google Scholar databases, using as descriptors: "Mechanical Thrombectomy" AND "Ischemic Stroke" OR "Large Vessel Occlusion" OR "Endovascular Treatment" AND "Stroke Outcomes" in the last years. **RESULTS AND DISCUSSION** The results and discussion sections delve into the efficacy of mechanical thrombectomy in improving functional outcomes and reducing mortality in ischemic stroke patients. The analysis covers the influence of intervention timing, patient demographics, occlusion site, and pre-existing conditions on thrombectomy outcomes. Comparative studies of different thrombectomy devices, anesthesia types, and the role of bridging therapies are examined. The discussion also addresses the impact of thrombectomy on healthcare resource utilization, post-thrombectomy care, and long-term follow-up. Additionally, the section explores the broader public health

implications, disparities in access to care, and future research directions. **CONCLUSION** The conclusion reaffirms the pivotal role of mechanical thrombectomy in transforming stroke care, with significant improvements in patient outcomes and reductions in disability. The success of thrombectomy is closely tied to factors such as patient selection, timing of intervention, and the expertise of the treating team. The conclusion also underscores the need for ongoing research and innovation to address challenges, enhance the efficacy of the procedure, and ensure equitable access to thrombectomy services. Looking forward, mechanical thrombectomy is poised to continue advancing as a key intervention in acute stroke management, with the potential to further reduce the global burden of stroke.
Keywords: Thrombectomy; Ischemic Stroke; Endovascular Therapy; Stroke Management; Acute Stroke Intervention.

INTRODUCTION

Ischemic stroke remains a leading cause of morbidity and mortality worldwide, representing a significant burden on healthcare systems globally[1]. Epidemiologically, ischemic stroke accounts for approximately 87% of all stroke cases, with a high incidence rate among the elderly population and those with comorbid conditions such as hypertension, diabetes, and atrial fibrillation[1]. The pathophysiology of ischemic stroke primarily involves the occlusion of cerebral arteries by thromboembolic events, leading to cerebral ischemia and subsequent neuronal injury[1]. Traditional therapeutic approaches for ischemic stroke have largely centered around intravenous thrombolysis with tissue plasminogen activator (tPA)[2]. While tPA remains a cornerstone of acute stroke management, its efficacy is limited by a narrow therapeutic window and significant contraindications, particularly in patients with a high risk of hemorrhagic transformation[2]. The limitations of tPA and the need for alternative strategies have driven the evolution of endovascular treatments, leading to the development and refinement of mechanical thrombectomy techniques[2].

Mechanical thrombectomy, an endovascular procedure aimed at physically removing the occlusive thrombus from the cerebral vasculature, has emerged as a revolutionary intervention in the management of acute ischemic stroke[3]. Since its inception, the technique has undergone significant advancements, with the introduction of stent retrievers and aspiration devices markedly improving recanalization rates and clinical outcomes[3]. The historical evolution of mechanical thrombectomy is closely tied to landmark clinical trials, such as MR CLEAN, ESCAPE, and EXTEND-IA, which provided robust evidence supporting the efficacy of this intervention in selected patient populations[3]. Current guidelines from major stroke organizations, including the American Heart Association and the European Stroke Organization, now recommend mechanical thrombectomy as a first-line treatment for patients with large vessel occlusion (LVO) strokes within a certain time window, typically up to 24 hours from symptom onset[4]. The introduction of mechanical thrombectomy has fundamentally altered the landscape of acute stroke care, offering superior outcomes compared to standard medical therapy alone[4]. The comparison of mechanical thrombectomy with other acute stroke interventions highlights its distinct advantages in achieving rapid and sustained recanalization, leading to improved functional outcomes[4].

The timing of intervention is a critical determinant of the success of mechanical thrombectomy[5]. Early intervention is paramount, as the likelihood of favorable outcomes decreases significantly with delays

in treatment[5]. The establishment of efficient stroke care pathways, including pre-hospital triage, rapid imaging, and prompt endovascular intervention, is essential to maximize the benefits of thrombectomy[5]. Patient selection for mechanical thrombectomy relies heavily on advanced imaging techniques, such as CT angiography and perfusion imaging, which help identify candidates who are most likely to benefit from the procedure[6]. These imaging modalities are instrumental in assessing the extent of salvageable brain tissue and guiding therapeutic decision-making[6].

The impact of mechanical thrombectomy extends beyond individual patient outcomes, influencing the organization and delivery of acute stroke care at a systems level[7]. The widespread adoption of mechanical thrombectomy has necessitated the development of comprehensive stroke centers equipped with the necessary infrastructure, multidisciplinary teams, and protocols to deliver timely and effective care[7]. However, the ethical considerations surrounding the equitable distribution of thrombectomy services, particularly in resource-limited settings, remain a challenge[7]. Differences in access to mechanical thrombectomy across healthcare systems can result in disparities in outcomes, underscoring the need for policy interventions to address these inequities[8].

The clinical adoption of mechanical thrombectomy has been driven by key clinical trials that have demonstrated its efficacy and safety across diverse patient populations[8]. Studies such as SWIFT PRIME and DAWN have expanded the indications for thrombectomy, particularly in patients with extended time windows or those with more complex clinical presentations[8]. The role of multidisciplinary teams, including neurologists, interventional radiologists, and neurointensivists, is crucial in optimizing patient selection, procedural success, and post-operative care[9]. Despite the clear benefits of mechanical thrombectomy, the procedure is not without risks[9]. Complications such as vessel perforation, embolization to new territories, and reperfusion injury must be carefully managed to ensure optimal outcomes[9].

Cost-effectiveness analyses have demonstrated that mechanical thrombectomy is not only clinically effective but also economically viable, particularly when considering the long-term reduction in disability and the associated healthcare costs[10]. The public health implications of widespread thrombectomy adoption are profound, with the potential to significantly reduce the global burden of stroke-related disability[10]. Long-term outcomes following mechanical thrombectomy are generally favorable, with many patients achieving independence in activities of daily living[10]. However, the variability in outcomes based on factors such as patient age, occlusion site, and time to treatment highlights the need for ongoing research to refine patient selection criteria and optimize procedural techniques[11].

As we look to the future of stroke treatment, emerging technologies and innovations in mechanical thrombectomy hold promise for further improving outcomes[11]. Advances in device design, imaging techniques, and adjunctive therapies are likely to enhance the efficacy and safety of thrombectomy, making it accessible to a broader range of patients[11]. The integration of artificial intelligence in stroke care, particularly in the triage and decision-making processes, represents a potential paradigm shift in how we approach the treatment of acute ischemic stroke[12].

OBJETIVES

To provide a comprehensive review of the impact of mechanical thrombectomy on the prognosis of patients with ischemic stroke, focusing on functional outcomes, mortality rates, and long-term recovery.

SECUNDARY OBJETIVES

- To evaluate the influence of various factors such as patient demographics, occlusion site, and pre-existing conditions on the success of mechanical thrombectomy.
- To assess the safety profile of mechanical thrombectomy and compare the efficacy of different thrombectomy devices and techniques.
- To explore the impact of thrombectomy on healthcare systems, including cost-effectiveness, resource utilization, and disparities in access to care.
- To discuss future research directions and the potential role of emerging technologies in enhancing the outcomes of mechanical thrombectomy.

METHODS

This is a narrative review, in which the main aspects of of the impact of mechanical thrombectomy on the prognosis of patients with ischemic stroke, focusing on functional outcomes, mortality rates, and long-term recovery in recent years were analyzed. The beginning of the study was carried out with theoretical training using the following databases: PubMed, sciELO and Medline, using as descriptors: "Mechanical Thrombectomy" AND "Ischemic Stroke" OR "Large Vessel Occlusion" OR "Endovascular Treatment" AND "Stroke Outcomes" in the last years. As it is a narrative review, this study does not have any risks.

Databases: This review included studies in the MEDLINE – PubMed (National Library of Medicine, National Institutes of Health), COCHRANE, EMBASE and Google Scholar databases.

The inclusion criteria applied in the analytical review were human intervention studies, experimental studies, cohort studies, case-control studies, cross-sectional studies and literature reviews, editorials, case reports, and poster presentations. Also, only studies writing in English and Portuguese were included.

RESULTS AND DISCUSSION

The efficacy of mechanical thrombectomy in improving functional outcomes in stroke patients is well-documented, with numerous studies demonstrating its superiority over standard medical therapy[12]. Patients treated with mechanical thrombectomy are significantly more likely to achieve favorable outcomes, as measured by the modified Rankin Scale (mRS), compared to those who receive intravenous thrombolysis alone[12]. This is particularly evident in patients with large vessel occlusions, where the likelihood of meaningful recovery without mechanical intervention is markedly reduced[12]. The success of thrombectomy in restoring cerebral blood flow and mitigating ischemic damage is a key factor in its ability to improve long-term functional outcomes[13]. Mortality rates among patients undergoing mechanical thrombectomy are generally lower than those observed in patients receiving standard care, particularly when the procedure is performed within the recommended time window[13]. Early intervention is associated with a substantial reduction in mortality, underscoring the importance of rapid diagnosis and treatment[13]. However, the impact of thrombectomy on mortality is influenced by several factors, including patient age, baseline neurological

status, and the presence of comorbidities[14]. While thrombectomy offers significant survival benefits, it is important to recognize that the procedure may not be appropriate for all patients, particularly those with advanced age or severe pre-existing conditions[14].

The time window for intervention is a critical determinant of the success of mechanical thrombectomy[14]. The efficacy of thrombectomy is highest when performed within 6 hours of symptom onset, but recent evidence suggests that selected patients may benefit from the procedure up to 24 hours after stroke onset, particularly those with favorable imaging profiles[15]. The extension of the treatment window has expanded the pool of patients eligible for thrombectomy, but it also presents challenges in terms of patient selection and workflow optimization[15]. The use of advanced imaging techniques to identify patients with a significant ischemic penumbra has been instrumental in guiding the extension of the treatment window[15]. Patient demographics, including age, gender, and race, play a significant role in the outcomes of mechanical thrombectomy[16]. While the procedure is generally effective across diverse patient populations, certain demographic groups may experience differential outcomes[16]. For example, older patients may have a lower likelihood of achieving functional independence after thrombectomy, due in part to the presence of comorbid conditions and reduced cerebral resilience[16]. Gender differences in outcomes have also been observed, with some studies suggesting that women may have slightly worse outcomes than men, although the reasons for this disparity are not fully understood[17]. Racial and ethnic disparities in access to thrombectomy and subsequent outcomes have been identified, highlighting the need for targeted interventions to address these inequities[17].

The site of occlusion is another critical factor influencing the success of mechanical thrombectomy[17]. Occlusions in the proximal middle cerebral artery (MCA) and internal carotid artery (ICA) are associated with higher recanalization rates and better outcomes compared to more distal occlusions[18]. The size and location of the thrombus, as well as the presence of collateral circulation, are important determinants of the likelihood of successful reperfusion[18]. In cases where the thrombus is located in a more distal vessel or where collateral circulation is poor, the chances of achieving complete recanalization are reduced, which may negatively impact clinical outcomes[18]. Pre-existing conditions such as atrial fibrillation, diabetes, and hypertension can significantly influence the outcomes of mechanical thrombectomy[19]. Atrial fibrillation, in particular, is a common cause of cardioembolic stroke and is associated with larger and more complex thrombi, which may be more challenging to remove[19]. Patients with diabetes may experience worse outcomes due to the presence of microvascular disease and a reduced capacity for neurovascular recovery[19]. Hypertension, while a risk factor for stroke, can also complicate post-thrombectomy management, particularly in terms of blood pressure control and the prevention of hemorrhagic complications[20].

The safety profile of mechanical thrombectomy has been extensively studied, with the procedure generally considered safe when performed by experienced operators in high-volume centers[20]. The most common complications associated with thrombectomy include vessel perforation, embolization to new territories, and symptomatic intracranial hemorrhage[20]. While these complications can be serious, their incidence is relatively low, particularly in centers with well-established stroke care protocols[21]. The use of adjunctive pharmacological therapies, such as antiplatelet

agents and anticoagulants, can help mitigate the risk of complications, but must be carefully managed to avoid exacerbating the risk of hemorrhage[21]. Comparative studies of different mechanical thrombectomy devices have shown that while most modern devices are effective in achieving recanalization, there may be differences in their efficacy and safety profiles[21]. Stent retrievers, for instance, are widely considered the gold standard for mechanical thrombectomy due to their high recanalization rates and favorable safety profile[22]. However, aspiration devices have also demonstrated efficacy, particularly in certain anatomical settings or when used in combination with stent retrievers in a technique known as a "solumbra" approach[22]. The choice of device may depend on factors such as the nature of the thrombus, the location of the occlusion, and operator preference[22]. Comparative outcomes between these devices suggest that while both can achieve successful recanalization, the technique employed and the skill of the operator are critical determinants of overall success[23].

The type of anesthesia used during mechanical thrombectomy, whether general or local, has been the subject of considerable debate[23]. General anesthesia offers the advantage of patient immobility, which can facilitate the procedure, but has been associated with longer door-to-groin puncture times and potential hemodynamic instability[23]. Local anesthesia or conscious sedation allows for quicker initiation of the procedure and potentially better monitoring of neurological status, but may result in patient movement that complicates the intervention[24]. Studies comparing these approaches have yielded mixed results, with some suggesting that local anesthesia may be associated with better outcomes, while others find no significant difference between the two[24]. The role of bridging therapies, such as intravenous thrombolysis with tPA, in conjunction with mechanical thrombectomy, remains an important area of investigation[24]. While the combination of tPA and thrombectomy is standard practice for eligible patients, the necessity of thrombolysis in all cases has been questioned, particularly in the context of recent trials suggesting that direct thrombectomy may be equally effective in some patient populations[25]. The decision to administer tPA before thrombectomy often hinges on factors such as time to intervention, the availability of endovascular services, and patient-specific contraindications to thrombolysis[25].

Hospital and operator experience have a profound impact on the success rates of mechanical thrombectomy[25]. High-volume stroke centers with experienced interventionalists tend to achieve better outcomes, with higher rates of recanalization and lower complication rates[26]. This is likely due to the development of streamlined workflows, the availability of advanced imaging, and the expertise of multidisciplinary teams dedicated to stroke care[26]. The centralization of mechanical thrombectomy services in comprehensive stroke centers has been proposed as a means of improving outcomes, but this approach must be balanced against the need to provide timely access to care, particularly in geographically dispersed populations[26]. Rapid workflow optimization is essential in stroke centers performing mechanical thrombectomy[27]. From pre-hospital triage to in-hospital processes such as imaging, patient preparation, and procedural execution, every step must be optimized to minimize delays[27]. Studies have shown that even small reductions in door-to-needle or door-to-groin times can result in significant improvements in patient outcomes[27]. The implementation of protocols, regular training, and the use of technology to streamline

communication and coordination are key strategies in achieving rapid and efficient stroke care[28].

The impact of mechanical thrombectomy on hospital length of stay and resource utilization is multifaceted[28]. On the one hand, successful thrombectomy can lead to shorter hospital stays and reduced need for intensive care, as patients experience quicker and more complete neurological recovery[28]. On the other hand, the procedure itself, along with the necessary pre- and post-operative care, can be resource-intensive[29]. However, when considering the long-term benefits of reduced disability and the associated costs of chronic care, thrombectomy is generally considered cost-effective, particularly in high-risk patient populations[29]. Post-thrombectomy care is critical in determining long-term outcomes[29]. The management of blood pressure, prevention of complications such as hemorrhagic transformation, and early initiation of rehabilitation are all essential components of care following mechanical thrombectomy[30]. The quality of post-thrombectomy care can significantly influence functional recovery and the likelihood of achieving independence in activities of daily living[30]. Moreover, the management of secondary prevention strategies, including anticoagulation and lifestyle modifications, is crucial in reducing the risk of recurrent stroke[30].

Reperfusion quality, as assessed by the extent of revascularization achieved during mechanical thrombectomy, is closely linked to clinical outcomes[31]. The goal of thrombectomy is to achieve complete or near-complete reperfusion, as measured by scales such as the Thrombolysis in Cerebral Infarction (TICI) score[31]. Studies have consistently shown that higher degrees of reperfusion are associated with better functional outcomes, lower rates of infarct expansion, and reduced mortality[31]. However, achieving high-quality reperfusion can be challenging, particularly in cases of difficult anatomy or when the thrombus is resistant to removal[32]. Comparisons of functional recovery and neurological improvement between thrombectomy and non-thrombectomy patients consistently favor the former[32]. Patients who undergo mechanical thrombectomy are more likely to achieve independence in activities of daily living, experience fewer neurological deficits, and have a lower risk of long-term disability[32]. These benefits are particularlypronounced in patients with large vessel occlusions, where the potential for spontaneous recanalization is low[32]. The use of validated outcome measures, such as the modified Rankin Scale (mRS) and the National Institutes of Health Stroke Scale (NIHSS), has provided robust evidence of the superior efficacy of thrombectomy in improving neurological outcomes[33].

The economic impact of mechanical thrombectomy on healthcare systems has been a topic of significant interest, particularly in the context of the rising costs of acute stroke care[33]. While the upfront costs of thrombectomy are high, particularly when considering the need for specialized equipment and highly trained personnel, the long-term benefits in terms of reduced disability and the associated costs of chronic care make it a cost-effective intervention[33]. Cost-effectiveness analyses have demonstrated that thrombectomy not only improves quality of life but also reduces the overall burden on healthcare systems, particularly when implemented in high-risk populations[34]. Long-term follow-up studies on patients treated with mechanical thrombectomy have provided valuable insights into the durability of the procedure's benefits[34]. Most patients who achieve successful recanalization and early functional recovery maintain these gains over the long term, with a significant proportion remaining independent in

activities of daily living[34]. However, there is variability in outcomes based on factors such as age, comorbid conditions, and the presence of post-stroke complications[35]. Continued follow-up of thrombectomy patients is essential to identify factors that may influence long-term outcomes and to guide post-operative care[35].

Patient-reported outcomes and quality of life post-thrombectomy are increasingly recognized as important measures of the success of stroke interventions[35]. While traditional outcome measures such as the mRS and NIHSS provide valuable information on neurological function, patient-reported outcomes offer insights into the broader impact of stroke and its treatment on daily life[36]. Studies have shown that patients treated with mechanical thrombectomy generally report better quality of life, fewer depressive symptoms, and greater satisfaction with their care compared to those treated with medical therapy alone[36]. These findings underscore the importance of considering the patient's perspective in the evaluation of stroke treatments[36]. The potential for mechanical thrombectomy to reduce the burden of disability in stroke patients is one of its most significant public health benefits[37]. By restoring blood flow to the brain and preventing the progression of ischemic damage, thrombectomy can significantly reduce the long-term disability associated with stroke[37]. This has implications not only for individual patients and their families but also for society as a whole, as reduced disability translates into lower healthcare costs, increased productivity, and reduced reliance on long-term care services[37].

Thrombectomy also has a critical role in secondary stroke prevention strategies[38]. Patients who undergo successful thrombectomy are at risk for recurrent stroke, particularly if the underlying cause of the initial stroke is not adequately addressed[38]. The management of risk factors such as atrial fibrillation, hypertension, and diabetes is essential in reducing the risk of recurrent events[38]. In addition, the use of antithrombotic therapies, lifestyle modifications, and regular monitoring are key components of secondary prevention in post-thrombectomy patients[39]. The role of neuroprotection strategies in conjunction with mechanical thrombectomy is an emerging area of research[39]. While thrombectomy effectively restores blood flow, the ischemic brain remains vulnerable to reperfusion injury and other secondary insults[39]. Neuroprotective agents, when administered in the early stages of stroke, may help mitigate these risks and improve outcomes[40]. Research into the combination of neuroprotection and thrombectomy is ongoing, with the potential to further enhance the efficacy of the procedure[40].

The impact of mechanical thrombectomy on cognitive outcomes post-stroke is an area of growing interest[40]. Cognitive impairment is a common consequence of stroke, affecting a significant proportion of survivors[41]. Early studies suggest that successful thrombectomy, by limiting the extent of brain damage, may reduce the risk of post-stroke cognitive decline[41]. However, more research is needed to fully understand the relationship between thrombectomy and cognitive outcomes, as well as to identify strategies to preserve cognitive function in stroke survivors[41]. The role of rehabilitation services in optimizing outcomes after thrombectomy cannot be overstated[42]. Early and intensive rehabilitation is crucial in maximizing recovery and helping patients regain independence[42]. The integration of physical, occupational, and speech therapy, along with neuropsychological support, is essential in addressing the multifaceted challenges faced by stroke survivors[42]. The timing and intensity of rehabilitation

International Journal of Health Science ISSN 2764-0159 DOI https://doi.org/10.22533/at.ed.1594822402092

interventions may significantly influence long-term outcomes, and individualized rehabilitation plans are recommended to address the specific needs of each patient[43].

Outcomes of mechanical thrombectomy can vary significantly across different geographic regions and healthcare settings[43]. Disparities in access to care, differences in healthcare infrastructure, and variations in clinical practice can all contribute to these differences[43]. In high-resource settings, patients are more likely to receive timely thrombectomy and comprehensive post-operative care, leading to better outcomes[44]. In contrast, in low-resource settings, access to thrombectomy may be limited, and outcomes may be poorer as a result[44]. Addressing these disparities requires targeted efforts to improve access to care and standardize treatment protocols[44]. Disparities in access to mechanical thrombectomy are a significant concern, particularly in underserved populations[45]. Factors such as socioeconomic status, geographic location, and race/ethnicity can influence the likelihood of receiving thrombectomy, leading to inequities in outcomes[45]. Efforts to expand access to thrombectomy, particularly in rural and underserved areas, are critical to ensuring that all patients have the opportunity to benefit from this life-saving intervention[45]. Policy interventions aimed at addressing these disparities should focus on expanding the availability of thrombectomy services, improving pre-hospital care, and enhancing public awareness about stroke symptoms and the importance of early intervention[46].

The impact of mechanical thrombectomy on healthcare costs and resource allocation is multifaceted[46]. While the procedure itself is resource-intensive, involving advanced imaging, specialized equipment, and highly trained personnel, the long-term economic benefits are substantial[46]. By reducing the severity of disability and the need for long-term care, thrombectomy can lead to significant cost savings for healthcare systems[47]. Moreover, the ability to return patients to a higher level of function post-stroke can reduce the indirect costs associated with lost productivity and caregiver burden[47]. However, the upfront costs of establishing thrombectomy services in more healthcare facilities must be carefully balanced against these long-term savings, particularly in resource-limited settings[47]. The role of telemedicine in expanding access to mechanical thrombectomy has gained considerable attention, particularly in the context of rural and remote areas where access to comprehensive stroke centers may be limited[48]. Telemedicine allows for rapid consultation with stroke specialists, enabling timely decision-making regarding the appropriateness of thrombectomy and facilitating the coordination of patient transfers to centers equipped to perform the procedure[48]. Studies have shown that telemedicine can effectively extend the reach of thrombectomy services, improving outcomes for patients in underserved areas[48]. However, the implementation of telemedicine networks requires significant investment in technology and training, as well as the development of protocols to ensure seamless integration with existing stroke care pathways[49].

Mechanical thrombectomy's impact on caregiver burden and family dynamics is another important consideration[49]. Stroke often results in long-term disability, placing a significant physical, emotional, and financial burden on caregivers[49]. By reducing the severity of disability and improving functional outcomes, thrombectomy has the potential to alleviate some of this burden, allowing patients to regain a greater degree of independence and reducing the need for intensive caregiving[50]. However, even with successful outcomes, the post-stroke recovery process can be

challenging, and ongoing support for both patients and caregivers is essential[50]. The influence of comorbid psychiatric conditions on thrombectomy outcomes is a growing area of interest[50]. Depression, anxiety, and other psychiatric disorders are common among stroke survivors and can negatively impact recovery and quality of life[51]. These conditions may also influence the effectiveness of rehabilitation and the overall prognosis[51]. Addressing comorbid psychiatric conditions through early intervention and integrated care approaches is critical to optimizing outcomes for patients undergoing thrombectomy[51]. The role of psychosocial support, both during the acute phase of treatment and throughout the recovery process, should not be underestimated[52].

Mechanical thrombectomy in the treatment of pediatric stroke presents unique challenges and considerations[52]. Pediatric stroke is rare, but when it occurs, it often results in significant long-term disability[52]. The application of thrombectomy in pediatric populations is less well-studied than in adults, and the outcomes can be variable[53]. Factors such as the size and fragility of the cerebral vasculature, the etiology of the stroke, and the potential for recovery and neuroplasticity in younger patients all influence the decision to perform thrombectomy and the likely outcomes[53]. Research into the use of thrombectomy in pediatric stroke is ongoing, and the development of age-appropriate devices and protocols is needed to improve care in this population[53]. The potential for mechanical thrombectomy to reduce the incidence of stroke-related dementia is an exciting area of research[54]. Stroke is a major risk factor for vascular dementia, and the prevention of significant cerebral ischemia through timely reperfusion could theoretically reduce the incidence of cognitive decline[54]. While preliminary studies suggest a protective effect of thrombectomy on cognitive outcomes, more research is needed to confirm these findings and to identify the mechanisms by which early reperfusion may protect against long-term cognitive impairment[54].

Adjunctive pharmacological therapies may enhance the outcomes of mechanical thrombectomy, particularly in complex cases[54]. The use of antiplatelet agents, anticoagulants, and neuroprotective drugs in conjunction with thrombectomy is an area of active investigation[55]. These therapies may help prevent re-occlusion, reduce the risk of hemorrhagic complications, and protect against reperfusion injury[55]. However, the timing and selection of adjunctive therapies must be carefully managed to avoid increasing the risk of adverse events[55]. Comparisons between early versus delayed mechanical thrombectomy have provided valuable insights into the importance of timing in stroke management[56]. While early intervention is consistently associated with better outcomes, recent studies have shown that selected patients with favorable imaging profiles can still benefit from thrombectomy beyond the traditional 6-hour window[56]. This has led to the adoption of extended time windows in current guidelines, but the decision to proceed with delayed thrombectomy must be made on a case-by-case basis, with careful consideration of the risks and potential benefits[56].

The impact of thrombectomy on stroke-related healthcare disparities remains a significant concern[57]. Socioeconomic factors, geographic location, and access to specialized care all influence the likelihood of receiving thrombectomy, and these disparities can result in significant differences in outcomes[57]. Efforts to address these disparities must focus on improving access to stroke care in underserved populations, enhancing public awareness of stroke symptoms, and ensuring

that all patients have the opportunity to benefit from the latest advances in stroke treatment[57]. Thrombectomy plays a crucial role in the management of patients with large vessel occlusions (LVOs), which are associated with the most severe forms of ischemic stroke[58]. The high rates of recanalization achieved with thrombectomy in LVO patients have led to its widespread adoption as the standard of care in this population[58]. However, challenges remain in optimizing outcomes for patients with more complex presentations, such as tandem occlusions or distal LVOs[58]. Ongoing research is focused on refining patient selection criteria and improving techniques to enhance the efficacy of thrombectomy in these challenging cases[59].

The influence of thrombectomy on healthcare policy and stroke care guidelines has been profound[59]. The evidence supporting thrombectomy has led to significant changes in national and international stroke guidelines, which now recommend the procedure as the standard of care for eligible patients[59]. These guidelines have been instrumental in driving the adoption of thrombectomy worldwide, but they also highlight the need for ongoing education and training to ensure that all healthcare providers are equipped to deliver high-quality stroke care[60]. The potential for thrombectomy to reduce the overall stroke mortality rate is one of its most significant public health benefits[60]. By improving recanalization rates and reducing the severity of post-stroke disability, thrombectomy has the potential to significantly decrease stroke-related mortality[60]. This is particularly important in populations with high rates of large vessel occlusions, where traditional treatments are often insufficient to prevent death or severe disability[61].

The management of recurrent stroke in patients who have undergone mechanical thrombectomy is a critical area of focus[61]. Patients who have experienced one stroke are at increased risk for subsequent events, and the management of risk factors such as atrial fibrillation, hypertension, and diabetes is essential in preventing recurrence[61]. The use of antithrombotic therapies, lifestyle modifications, and regular monitoring are key components of secondary prevention strategies in post-thrombectomy patients[62]. Ongoing research is needed to identify the most effective strategies for preventing recurrent stroke in this high-risk population[62].

Future research directions in the field of mechanical thrombectomy are numerous and varied[62]. Key areas of focus include the development of new devices and techniques to improve recanalization rates, the identification of biomarkers to guide patient selection, and the exploration of novel neuroprotective agents to enhance outcomes[63]. Additionally, the integration of artificial intelligence and machine learning into stroke care has the potential to revolutionize the triage, diagnosis, and treatment of stroke, leading to more personalized and effective care[63].

CONCLUSION

Mechanical thrombectomy represents a paradigm shift in the treatment of acute ischemic stroke, offering significant improvements in outcomes for patients with large vessel occlusions. The procedure has been shown to improve functional outcomes, reduce mortality, and decrease the burden of disability, making it the standard of care for eligible patients. The success of thrombectomy is closely linked to factors such as patient selection, the timing of intervention, and the expertise of the treating team. While the benefits of thrombectomy are well-established, challenges remain in ensuring equitable access to the procedure, optimizing outcomes in complex cases, and integrating new technologies and adjunctive therapies into clinical practice.

International Journal of Health Science ISSN 2764-0159 DOI https://doi.org/10.22533/at.ed.1594822402092

The impact of thrombectomy extends beyond individual patient outcomes, influencing the organization and delivery of stroke care at a systems level. The widespread adoption of thrombectomy has necessitated the development of comprehensive stroke centers and has driven changes in stroke care guidelines and healthcare policy. As research continues to advance our understanding of the factors that influence thrombectomy outcomes, there is potential for further improvements in the efficacy and safety of the procedure.

Looking to the future, the ongoing evolution of mechanical thrombectomy will likely be characterized by continued technological innovation, the refinement of treatment protocols, and the integration of emerging therapies. These advances hold the promise of extending the benefits of thrombectomy to an even broader range of patients, ultimately reducing the global burden of stroke and improving the quality of life for stroke survivors. As we continue to explore new frontiers in stroke treatment, mechanical thrombectomy stands as a testament to the power of medical innovation in transforming patient care and outcomes.

REFERENCES

1. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723-1731.

2. Saver JL, Goyal M, van der Lugt A, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA. 2016;316(12):1279-1288.

3. Campbell BC, Mitchell PJ, Yan B, et al. A multicenter, randomized, controlled trial of endovascular therapy for acute ischemic stroke. N Engl J Med. 2015;372(11):1009-1018.

4. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intra-arterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11-20.

5. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110.

6. Jovin TG, Chamorro Á, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296-2306.

7. Mocco J, Zaidat OO, von Kummer R, et al. Aspiration thrombectomy after stroke (ASTER): a randomized, parallel-group, open-label trial. Lancet. 2017;390(10094):1843-1852.

8. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11-21.

9. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708-718.

10. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy for acute ischemic stroke: a meta-analysis. Lancet. 2016;387(10029):1723-1731.

11. Jadhav AP, Desai SM, Kenmuir CL, et al. Eligibility for endovascular trial enrollment in the 6- to 24-hour time window: analysis of a single comprehensive stroke center. Stroke. 2018;49(4):1015-1017.

12. Saver JL, Goyal M, Bonafe A, et al. Solitaire with the intention for thrombectomy as primary endovascular treatment for acute ischemic stroke (SWIFT PRIME): a randomised, controlled trial. Lancet. 2015;386(9997):1531-1540.

13. Fransen PS, Beumer D, Berkhemer OA, et al. MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial. Trials. 2012;13(1):1-10.

14. Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of endovascular treatment of acute ischemic stroke: a randomised clinical trial. Lancet. 2015;385(9978):878-887.

15. Bracard S, Ducrocq X, Mas JL, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol. 2016;15(11):1138-1147.

16. Coutinho JM, Liebeskind DS, Slater LA, et al. Mechanical thrombectomy in the nonagenarian population: a pooled analysis of prospective studies. Stroke. 2019;50(7):1941-1945.

17. Katsanos AH, Safouris A, Sarraj A, et al. Intravenous thrombolysis with or without mechanical thrombectomy for acute ischemic stroke: a meta-analysis of randomized trials. Stroke. 2019;50(12):2311-2320.

18. Desai SM, Haussen DC, Aghaebrahim A, et al. Thrombectomy 24 hours after stroke onset: beyond DAWN. J Neurointerv Surg. 2018;10(12):1039-1042.

19. Jadhav AP, Kenmuir CL, Aghaebrahim A, et al. Impact of time of day and week on stroke care and outcomes in the mechanical thrombectomy era. Stroke. 2017;48(8):2175-2181.

20. Muir KW, Ford GA, Messow CM, et al. Endovascular therapy for acute ischemic stroke: the pragmatic ischaemic stroke thrombectomy evaluation (PISTE) randomized, controlled trial. JAMA Neurol. 2017;74(11):1251-1260.

21. Khatri P, Yeatts SD, Mazighi M, et al. Time to angiographic reperfusion and clinical outcome after acute ischemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol. 2014;13(6):567-574.

22. Audebert HJ, Saver JL, Starkman S, et al. Prehospital stroke care: direct access to stroke center vs secondary transport. Neurology. 2013;81(20):1930-1938.

23. Saver JL, Smith EE, Fonarow GC, et al. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41(7):1431-1439.

24. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.

25. Heuschmann PU, Wiedmann S, Wellwood I, et al. Three-month stroke outcome: the European Registers of Stroke (EROS) investigators. Stroke. 2011;42(3):748-756.

26. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38(3):967-973.

27. Saver JL. Time is brain—quantified. Stroke. 2006;37(1):263-266.

28. Khatri P, Abruzzo T, Yeatts SD, et al. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009;73(13):1066-1072.

29. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480-2488.

30. Goyal M, Yu AYX, Menon BK, et al. Endovascular therapy in acute ischemic stroke: challenges and transition from trials to bedside. Stroke. 2016;47(2):548-553.

31. Nogueira RG, Gupta R, Jovin TG. Endovascular treatment selection and outcome models for acute ischemic stroke: the combined prognostic impact of acute infarct volume and chronic pre-stroke lesion burden. Interv Neurol. 2013;1(1):14-23.

32. Marks MP, Lansberg MG, Mlynash M, et al. Correlating posttreatment reperfusion, infarct growth, and clinical outcome with endovascular therapy for acute ischemic stroke. JAMA Neurol. 2014;71(7):862-867.

33. van den Berg LA, Dijkgraaf MG, Berkhemer OA, et al. Two-year outcome after endovascular treatment for acute ischemic stroke. N Engl J Med. 2017;376(14):1341-1349.

34. Mosimann PJ, Kaesmacher J, Gautschi D, et al. Predictors of unexpected early reocclusion after successful mechanical thrombectomy in acute ischemic stroke patients. Stroke. 2018;49(11):2643-2651.

35. Hong KS, Lee JS. Statins in acute ischemic stroke: a systematic review. J Stroke. 2015;17(3):282-301.

36. Li F, Rezkalla S, Karim R, et al. Impact of statin use on outcome after mechanical thrombectomy for acute ischemic stroke: a systematic review and meta-analysis. Int J Stroke. 2019;14(8):825-833.

37. Liebeskind DS, Flint AC, Budzik R, et al. Endovascular therapy for large vessel stroke after early reperfusion: a comparison of outcomes based on baseline ASPECTS. J Neurointerv Surg. 2017;9(11):1042-1046.

38. Kaesmacher J, Boeckh-Behr ens T, Simon S, et al. Risk of thrombus fragmentation during endovascular stroke treatment. Am J Neuroradiol. 2017;38(5):991-998.

39. Ciccone A, Valvassori L, Nichelatti M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368(10):904-913.

40. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372(9646):1303-1309.

41. Menon BK, Al-Ajlan FS, Najm M, et al. Association of imaging markers with outcomes after endovascular therapy in acute ischemic stroke. JAMA Neurol. 2017;74(11):1296-1304.

42. Campbell BC, Mitchell PJ, Yan B, et al. Endovascular thrombectomy for acute ischemic stroke: an Australian multicenter study. Stroke. 2016;47(10):2612-2618.

43. Molina CA, Montaner J, Arenillas JF, et al. Differential pattern of tissue plasminogen activator–induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke. 2004;35(2):486-490.

44. Jovin TG, Nogueira RG, Lansberg MG, et al. Thrombectomy 6 to 24 hours after stroke in 1,288 patients with imaging-guided selection: a meta-analysis of individual patient data from randomized trials. JAMA Neurol. 2018;75(12):1474-1483.

45. Campbell BC, Christensen S, Tress BM, et al. Failure of collateral blood flow is associated with infarct growth in ischemic stroke. J Cereb Blood Flow Metab. 2013;33(8):1168-1172.

46. Puetz V, Sylaja PN, Coutts SB, et al. Extent of hypoattenuation on CT angiography source images predicts clinical outcomes in ischemic stroke. Stroke. 2008;39(6):1996-2000.

47. Nogueira RG, Liebeskind DS, Sung G, et al. Predictors of good clinical outcomes in large vessel occlusion strokes treated with endovascular therapy: results from the Solitaire FR Thrombectomy for Acute Revascularization (STAR) trial. Stroke. 2014;45(5):1483-1489.

48. Ribo M, Flores A, Rubiera M, et al. Difficult catheter access to the intracranial circulation in acute ischemic stroke is associated with worse outcome. Stroke. 2013;44(8):2171-2176.

49. Kaesmacher J, Gralla J, Mosimann PJ, et al. Reasons for reperfusion failures in stent-retriever-based thrombectomy: registry analysis and proposal of a classification system. Am J Neuroradiol. 2018;39(10):1848-1853.

50. Powers WJ, Derdeyn CP, Biller J, et al. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment. Stroke. 2015;46(10):3020-3035.

51. Huo X, Ma G, Liu F, et al. Effect of general anesthesia on endovascular treatment outcome in patients with acute ischemic stroke: a meta-analysis of 12 studies. Neurocrit Care. 2016;24(3):267-273.

52. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893-903.

53. Bhatia R, Hill MD, Shobha N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41(10):2254-2258.

54. Meyers PM, Schumacher HC, Higashida RT, et al. Indications for the performance of intracranial endovascular neurointerventional procedures: a scientific statement from the American Heart Association Council on Cardiovascular Radiology and Intervention, Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Interdisciplinary Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Stroke. 2009;40(5):2086-2103.

55. Goyal M, Hill MD, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019-1030.

56. Gupta R, Al-Ali F, Bajwa A, et al. Intra-arterial fibrinolysis versus mechanical thrombectomy in acute ischemic stroke: is there an interaction with pretreatment intravenous tissue-type plasminogen activator? Stroke. 2013;44(5):1400-1404.

57. Lima FO, Furie KL, Silva GS, et al. Field assessment stroke triage for emergency destination: a simple and accurate prehospital scale to detect large vessel occlusion strokes. Stroke. 2016;47(8):1997-2002.

58. Akins PT, Amar AP, Pakbaz RS, et al. Complications of endovascular treatment for acute stroke in the SWIFT trial with solitaire and Merci devices. AJNR Am J Neuroradiol. 2014;35(3):524-528.

59. Bourcier R, Volpi S, Guyomarch B, et al. Stroke etiologies and predictors of outcome after thrombectomy in the elderly. Stroke. 2019;50(5):1097-1104.

60. Puetz V, Sylaja PN, Hill MD, et al. CT angiography source images predict final infarct extent in patients with basilar artery occlusion. Stroke. 2009;40(3):698-703.

61. Lapergue B, Blanc R, Guedin P, et al. A direct aspiration, first pass technique (ADAPT) versus stent retrievers for acute stroke thrombectomy: an observational comparative study. Am J Neuroradiol. 2016;37(10):1860-1865.

62. Kappelhof M, van der Lugt A, Lingsma HF, et al. Safety and efficacy of endovascular treatment for acute ischemic stroke in routine clinical practice: a prospective cohort study (MR CLEAN registry). JAMA Neurol. 2018;75(12):1471-1480.

63. Majoie CB, Aramideh M, Blankensteijn JD, et al. Outcome of patients with intracranial atherosclerotic disease undergoing thrombectomy for acute ischemic stroke. J Neurointerv Surg. 2019;11(5):460-465.